Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis.
暂无分享,去创建一个
[1] E. Schwarz,et al. Reduction of particle-induced osteolysis by interleukin-6 involves anti-inflammatory effect and inhibition of early osteoclast precursor differentiation. , 2009, Bone.
[2] J. Zwerina,et al. Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. , 2009, Arthritis and rheumatism.
[3] D. Burr,et al. Osteoblast Function Is Compromised at Sites of Focal Bone Erosion in Inflammatory Arthritis , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] F. Blanchard,et al. The dual role of IL-6-type cytokines on bone remodeling and bone tumors. , 2009, Cytokine & growth factor reviews.
[5] M. Oukka. Th17 cells in immunity and autoimmunity , 2008, Annals of the rheumatic diseases.
[6] M. Hashizume,et al. IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. , 2008, Rheumatology.
[7] J. David,et al. The role of Wnt proteins in arthritis , 2008, Nature Clinical Practice Rheumatology.
[8] C. Bäckesjö,et al. IL-6 receptor expression and IL-6 effects change during osteoblast differentiation. , 2008, Cytokine.
[9] Gang Wang,et al. Expression characteristic and significance of interleukin-6, nuclear factor kappa beta, and bone formation markers in rat models of osteoporosis. , 2008, Translational research : the journal of laboratory and clinical medicine.
[10] D. Heymann,et al. Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3. , 2008, Endocrinology.
[11] K. Ishihara,et al. Interleukin-6 Directly Inhibits Osteoclast Differentiation by Suppressing Receptor Activator of NF-κB Signaling Pathways* , 2008, Journal of Biological Chemistry.
[12] J. O’Shea,et al. Cytokine signaling modules in inflammatory responses. , 2008, Immunity.
[13] N. Pleshko Camacho,et al. Callus mineralization and maturation are delayed during fracture healing in interleukin-6 knockout mice. , 2007, Bone.
[14] D. M. van der Heijde,et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab , 2007, Annals of the rheumatic diseases.
[15] P. Miossec,et al. The role of T cells in rheumatoid arthritis: new subsets and new targets , 2007, Current opinion in rheumatology.
[16] Georg Schett,et al. Dickkopf-1 is a master regulator of joint remodeling , 2007, Nature Medicine.
[17] T. Kishimoto,et al. Interleukin 6: from bench to bedside , 2006, Nature Clinical Practice Rheumatology.
[18] A. Teti,et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. , 2006, Arthritis and rheumatism.
[19] T. Kishimoto,et al. Interleukin-6 : discovery of a pleiotropic cytokine , 2022 .
[20] P. Lipsky. Interleukin-6 and rheumatic diseases , 2006, Arthritis research & therapy.
[21] H. Weiner,et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.
[22] S. Goldring,et al. Rheumatic diseases: the effects of inflammation on bone , 2005, Immunological reviews.
[23] U. Müller-Ladner,et al. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. , 2005, Rheumatology.
[24] M. Malaise,et al. Interleukin-6: An osteotropic factor influencing bone formation? , 2005, Bone.
[25] J. Aubin,et al. GP130/OSMR is the only LIF/IL‐6 family receptor complex to promote osteoblast differentiation of calvaria progenitors , 2005, Journal of cellular physiology.
[26] P. Esbrit,et al. The Interleukin-6/Soluble Interleukin-6 Receptor System Induces Parathyroid Hormone–Related Protein in Human Osteoblastic Cells , 2004, Calcified Tissue International.
[27] T. Martin,et al. Glycoprotein 130 regulates bone turnover and bone size by distinct downstream signaling pathways. , 2004, The Journal of clinical investigation.
[28] S. Rose-John,et al. Soluble IL-6 Receptor Governs IL-6 Activity in Experimental Arthritis: Blockade of Arthritis Severity by Soluble Glycoprotein 130 , 2003, The Journal of Immunology.
[29] N. Athanasou,et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. , 2002, Bone.
[30] Y. Saeki,et al. A Point Mutation of Tyr-759 in Interleukin 6 Family Cytokine Receptor Subunit gp130 Causes Autoimmune Arthritis , 2002, The Journal of experimental medicine.
[31] U. Lerner,et al. IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-κB Ligand, Osteoprotegerin, and Receptor Activator of NF-κB in Mouse Calvariae1 , 2002, The Journal of Immunology.
[32] C. Benoist,et al. Critical Roles for Interleukin 1 and Tumor Necrosis Factor α in Antibody-induced Arthritis , 2002, The Journal of experimental medicine.
[33] John C. Lee,et al. Osteogenic protein‐1 and interleukin‐6 with its soluble receptor synergistically stimulate rat osteoblastic cell differentiation , 2002, Journal of cellular physiology.
[34] A R Pettit,et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. , 2001, The American journal of pathology.
[35] C. O’Brien,et al. Expression levels of gp130 in bone marrow stromal cells determine the magnitude of osteoclastogenic signals generated by IL‐6‐type cytokines , 2000, Journal of cellular biochemistry.
[36] D. Heymann,et al. gp130 Cytokine family and bone cells. , 2000, Cytokine.
[37] 梅下 光子. Delayed onset and reduced severity of collagen-induced arthritis in interleukin-6-deficient mice , 2000 .
[38] M. Baiocchi,et al. Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. , 1999, Cytokine.
[39] A. Verbruggen,et al. Flow cytometrical determination of interleukin 1beta, interleukin 6 and tumour necrosis factor alpha in monocytes of rheumatoid arthritis patients; relation with parameters of osteoporosis. , 1999, Cytokine.
[40] P. Miossec,et al. Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. , 1999, Arthritis and rheumatism.
[41] S. C. Lin,et al. Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. , 1998, Proceedings of the Association of American Physicians.
[42] G. Kollias,et al. Interleukin 6 Is Required for the Development of Collagen-induced Arthritis , 1998, The Journal of experimental medicine.
[43] N. Franchimont,et al. Interleukin-6 with its soluble receptor enhances the expression of insulin-like growth factor-I in osteoblasts. , 1997, Endocrinology.
[44] U. Müller-Ladner,et al. Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. , 1997, British journal of rheumatology.
[45] T. Vischer,et al. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. , 1997, The Journal of rheumatology.
[46] G. Ciliberto,et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. , 1997, Immunity.
[47] G. Ciliberto,et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. , 1997, The Journal of clinical investigation.
[48] G. Yancopoulos,et al. Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells. , 1996, The Journal of clinical investigation.
[49] N. Udagawa,et al. Interleukin‐6 and soluble interleukin‐6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast‐like cell formation , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[50] F. Takahashi,et al. Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. A cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow. , 1995, The American journal of pathology.
[51] S. Akira,et al. Interleukin-6 family of cytokines and gp130. , 1995, Blood.
[52] R. Zinkernagel,et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice , 1994, Nature.
[53] G. Ciliberto,et al. Interleukin‐6 deficient mice are protected from bone loss caused by estrogen depletion. , 1994, The EMBO journal.
[54] R. Madhok,et al. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. , 1993, Annals of the rheumatic diseases.
[55] T. Hirano,et al. Molecular cloning and expression of an IL-6 signal transducer, gp130 , 1990, Cell.
[56] J. Miyazaki,et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[57] T. Hirano,et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130 , 1989, Cell.
[58] F. Houssiau,et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. , 1988, Arthritis and rheumatism.
[59] I. Wicks,et al. Interleukin-6 modulates production of T lymphocyte-derived cytokines in antigen-induced arthritis and drives inflammation-induced osteoclastogenesis. , 2006, Arthritis and rheumatism.
[60] T. Sugiyama. Involvement of interleukin-6 and prostaglandin E2 in periarticular osteoporosis of postmenopausal women with rheumatoid arthritis , 2001, Journal of Bone and Mineral Metabolism.
[61] 大島 至郎. Interleukin 6 plays a key role in the development of antigen-induced arthritis , 1999 .
[62] B. Kirkham,et al. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. , 1992, The Journal of rheumatology.